Randomised trial shows no superiority of BCG plus mitomycin over BCG alone in non-muscle-invasive bladder cancer, suggesting a practical alternative.
BCG + MM was not proved superior to BCG alone, but required 39% fewer doses of BCG and fewer treatment discontinuations. These findings support consideration of BCG + MM as a pragmatic alternative to BCG alone, which could mitigate the global shortage of BCG.
No takes yet. Share an insight, caveat, or question.
Hayne et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: